Profile of Polycythemia Vera in Campus Teaching Hospital of Lome - Togo
Cancer Research Journal
Volume 4, Issue 1, January 2016, Pages: 24-27
Received: Jan. 29, 2016; Accepted: Feb. 8, 2016; Published: Feb. 29, 2016
Views 2953      Downloads 54
Authors
Padaro Essohana, Hematology, Campus Teaching Hospital of Lome, Lome, Togo; Faculty of Health Sciences, University of Lome, Lome, Togo
Kueviakoe Irenee Messanh Delagnon, Hematology, Campus Teaching Hospital of Lome, Lome, Togo; Hematology, Sylvanus Olympio Teaching Hospital of Lome, Lome, Togo; Faculty of Health Sciences, University of Lome, Lome, Togo
Layibo Yao, Hematology, Campus Teaching Hospital of Lome, Lome, Togo; Faculty of Health Sciences, University of Lome, Lome, Togo
Kolou Malewe, Hematology, Campus Teaching Hospital of Lome, Lome, Togo; Faculty of Health Sciences, University of Lome, Lome, Togo
Agbetiafa Kossi, Hematology, Campus Teaching Hospital of Lome, Lome, Togo; Faculty of Health Sciences, University of Lome, Lome, Togo
Stephane Giraudier, Biological Hematology Service, APHP Henri Mondor, University Paris XII, Creteil, France
Segbena Akuete Yvon, Hematology, Campus Teaching Hospital of Lome, Lome, Togo; Faculty of Health Sciences, University of Lome, Lome, Togo
Article Tools
Follow on us
Abstract
Objective: To describe the clinical, epidemiological and biological profile of polycythemia vera. Patients and methods: This is a descriptive study done from May to October 2014 witch included 13 patient who had been treated since 2007 at Campus Teaching Hospital of Lomé for polycythemia vera. The research of JAK2 V617Fmutation by PCR was been done inmolecular biologylaboratory of the Henri Mondor Hospital at Creteil in France. Results: The annual prevalence of polycythemia vera is about 2.16 new cases. The average age of patients was 46, 7 years with ranges from 31 to 65 years. There were 9 men and 4 women. The most frequent factor of finding was the fortuitous ones (23%). Most clinical signs represented were headache (69.2%), skin érythroses (53.8%) and paresthesia (30.8%). The average value of hemoglobin, hematocrit, the number of white blood cells and platelets in our patients with polycythemia who had positive JAK2V617F was respectively: 198g/L ± 44; 62.7 ± 4.4%; 9.8 G/L ± 4.3, 630.4G /l ± 367.4. Those Who didn’t had JAK2mutation, had respectively: 179g/L ± 13.3; 59,0% ± 13.3; 7.5G/L ± 4.2 GB and 441.0G /L ± 564.7. Conclusion: The JAK2V617F mutation had an interestin polycythemia vera value in diagnosis and can be systematic even in Sub-Saharan African.
Keywords
Polycythemia Vera, JAK 2 Changes, Lome (Togo)
To cite this article
Padaro Essohana, Kueviakoe Irenee Messanh Delagnon, Layibo Yao, Kolou Malewe, Agbetiafa Kossi, Stephane Giraudier, Segbena Akuete Yvon, Profile of Polycythemia Vera in Campus Teaching Hospital of Lome - Togo, Cancer Research Journal. Vol. 4, No. 1, 2016, pp. 24-27. doi: 10.11648/j.crj.20160401.13
Copyright
Copyright © 2016 Authors retain the copyright of this article.
This article is an open access article distributed under the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
References
[1]
PaHL. Towards a molecular understanding of polycythemia rubravera. Eur J Biochem 2000; 267: 3395-401.
[2]
Kralovics R, Guan Y, Prchal JT. Acquired uniparentaldisomy of chromosome 9p is a frequent stem cell defect in polycythemia vera. Exp Hematol 2002; 30: 229-36.
[3]
Vainchenker W, Casadevall N. «JAK» a dit: c’est un syndrome myéloprolifératif. Hématologie2006; 12: 4.
[4]
Ayad MW, Nafea D. Acquired mutation of the tyrosine kinase JAK2V617F in Egyptian patients with myeloid disorders. Genet Test Mol Biomarkers 2011; 15: 17-21.
[5]
Benmoussa A, Dehbi H, Fehri S, Quessar A, Nadifi S. JAK2-V617F mutation in Moroccan patients with myeloproliferative disorders: contribution, diagnosis and therapeutic prospects. Pathol Biol (Paris) 2011; 59: e89-92.
[6]
Padaro E, Agbetiafa K, Kueviakoe IMD, Layibo Y, Segbena AY, Sanogo I et al: Syndromes myéloprolifératifs «Philadelphienégatif» et mutation JAK2V617F:étude des 15 premiers casayant bénéficié de cette recherche au Togo. Ann BiolClin2012; 70 (5): 591-4.
[7]
Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO): classification of myeloid neoplasms. Blood2002; 100: 2292.
[8]
Télleri A, Vardman JW. Classification and diagnosis of myeloproliférativeneoplasme: the 2008 World Health Organisation and point of car diagnostic algorithms. Leukemia 2008: 22; 14-22.
[9]
Kiladjan JJ, Gardin C, Renoux M, Bruno F, Bernard JF. Long-term outcomes of polycytttthemiavrea patients treated with pipobroman as initial therapy. Hematol J 2003; 4: 198-207.
[10]
Kiladjian JJ, Cassinat B, Chevret S, Turlure P, Cambier N, Roussel M, et al. Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera. Blood 2008; 112: 3065-72.
[11]
Kiladjian JJ, Chomienne C, Fenaux P. Interferon-alpha therapy in bcr-abl-negative myeloproliferative neoplasms. Leukemia 2008; 22: 1990-8.
[12]
Kiladjian JJ. Diagnostic et traitement de la thrombocytémie primitive. Rev Prac2005; 55: 1671-9.
[13]
Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJ, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005; 7: 387-97.
[14]
Cassinat B. Laguillier C. Gardin C. de Beco V. Burcheri S. Fenaux P. et al. Classification of myeloproliferative disorders in the JAK2 era: is there a role for red cell mass? Leukemia 2008: 22: 452-3.28-.
[15]
Moliterno AR. Spivak JL Posttranslation processing of the Thrombopoietin receptor is impaired vera. Blood 1999; 94: 2555-61.
[16]
Sazawal S, Bajaj J, Chikkara S, Jain S, Bhargava R, Mahapatra M, et al. Prevalence of JAK2 V617F mutation in Indian patients with chronic myeloproliferative disorders. Indian J Med Res 2010; 132: 423-7.
[17]
Yuan LY, Li H, Chen GA, Ji DX, Gao LL, Rong JP, et al. Incidence of JAK2V617F mutation in myeloproliferative diseases and its clinical significance. Zhejiang Da Xue Xue Bao Yi Xue Ban 2010; 39: 202-6.
[18]
Knoops L, Hermans C, Ferrant A, Constantinescu SN. Clinical implications of JAK2 mutations in myeloproliferative disorders. Acta Clin Belg 2008; 63: 93-8.
[19]
Fiorina G, Luciana T, Maria LM, Maurizio M, Giovanna P, Angela A. Thrombocythemia and polycythemia in patients younger than 20 years at diagnosis: clinical and biologic features, treatment, and long-term outcome. Blood, 8 March 2012 _ Vol 119, Num 10 p9.
[20]
Mirza AM, Ezzat S, Axelrad AA, Insulin-like gzowth factor binding protein-1 is elevated in patients with polycythemia vera and stimulates erythroid burst formation in vitro. Blood 1997; 89: 1862-9.
[21]
Mutlu K, Tahsin Y, Vildan O, Fahir O, Ridvan A, Murat B et al. Evaluation of the JAK2-V617F gene mutation in Turkish patients with essential thrombocythemia and polycythemia vera. Mol Biol Rep (2012) 39: 8663–8667 Doi 10.1007/s11033-012-1721-x; 1-5 p.
[22]
Mahjoub S, Baccouche H, Sahnoun M, Kaabi H, Manai Z, Slama H, Ben Romdhane N. The JAK2 mutation in myeloproliferative neoplasms: A predictive factor of thrombosis. Tunis Med. 2015 Jul; 93(7): 474-7.
[23]
Parasuraman S, DiBonaventura M, Reith K, Naim A, Concialdi K, Sarlis NJ. Patterns of hydroxyurea use and clinical outcomes among patients with polycythemia vera in real-world clinical practice: a chart review. Exp Hematol Oncol. 2016 Feb 1; 5: 3.
[24]
Mutationsmasahirookabe, Hiroki Yamaguchi, Kensuke Usukib, Yutaka Kobayashi, Eri Kawatac, Junya Kuroda, Shinya Kimura et al Clinicalfeatures of Japanese polycythemia vera and essential thrombocythe mia patients harboring CALR, JAK2V617F, JAK2Ex12del, and MPLW515L/K mutations. Leukemia Research 40 (2016) 68–76.
[25]
Radia D, Geyer HL. Management of symptoms in polycythemia vera and essential thrombocythemia patients. Hematology Am Soc Hematol Educ Program. 2015 Dec 5; 2015(1): 340-8.
[26]
Okabe M, Yamaguchi H, Usuki K, Kobayashi Y, Kawata E, Kuroda J, Kimura S et al. Clinical features of Japanese polycythemia vera and essential thrombocythemia patients harboring CALR, JAK2V617F, JAK2Ex12del, and MPLW515L/K mutations. Leuk Res. 2016 Jan; 40: 68-76.
ADDRESS
Science Publishing Group
1 Rockefeller Plaza,
10th and 11th Floors,
New York, NY 10020
U.S.A.
Tel: (001)347-983-5186